LISATA THERAPEUTICS, INC. — Director's Dealing 2020

Sep 10, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CALADRIUS BIOSCIENCES, INC. (CLBS)
CIK: 0000320017
Period of Report: 2020-09-09

Reporting Person: Davidson Michael H. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-09-09	Common Stock	P	55525	$1.80	Acquired	106588	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transaction prices ranging from $1.74 to $1.84, inclusive. The reporting person undertakes to provide Caladrius Biosciences, Inc., any security holder of Caladrius Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F2: Includes 51,063 shares of unvested restricted stock units.